Crystagen
Also known as: Peptídeo imunológico
Molecular Identifiers
Overview
Immune system bioregulatory tripeptide developed by the Khavinson group. Regulates gene expression in immune cells and supports thymus-independent immunity. Used in short cycles for immune modulation and strengthening.
EDP Glu-Asp-Pro Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Regulation of gene expression in immune cells
- Support for thymus-independent immunity
- Modulation of lymphocyte and NK cell activity
- Normalization of cytokine production
- Bioregulatory effect on innate and adaptive immune system
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 5-10 mg per day via subcutaneous injection |
| Frequency | Once daily |
| Timing | Morning or as per protocol |
| Duration | 10-20 days, cycled 2-4 times per year |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Presentations & Preparation
Vials of Crystagen found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
100-500 mcg per injection (subcutaneous) · Once daily
Bronchogen
5-10 mg per day via subcutaneous injection · Once daily
Cardiogen
5-10 mg per day subcutaneously · Once daily
Chonluten
5-10 mg per day subcutaneously · Once daily
Dalargin
1-2 mg per injection (subcutaneous or intramuscular) · 1-2 times daily